TY - JOUR
T1 - New concepts regarding events that lead to end-stage heart disease
AU - Cohn, Jay N.
PY - 1995/8
Y1 - 1995/8
N2 - Cardiac dysfunction is a progressive process that eventuates in end-stage heart failure. This progression involves dilatation and hypertrophy of the left ventricle, characterized as left ventricular remodeling. This remodeling results in a falling left ventricular ejection fraction, worsening heart failure, and increased risk of lethal ventricular arrhythmias. Increased aortic impedance due to vasoconstriction, neurohormonal stimulation, and bioenergetic abnormalities all may contribute to the remodeling process. Therapeutic efforts aimed at halting this progressive process, especially if initiated early in the course of the disease, are most likely to exert a favorable effect.
AB - Cardiac dysfunction is a progressive process that eventuates in end-stage heart failure. This progression involves dilatation and hypertrophy of the left ventricle, characterized as left ventricular remodeling. This remodeling results in a falling left ventricular ejection fraction, worsening heart failure, and increased risk of lethal ventricular arrhythmias. Increased aortic impedance due to vasoconstriction, neurohormonal stimulation, and bioenergetic abnormalities all may contribute to the remodeling process. Therapeutic efforts aimed at halting this progressive process, especially if initiated early in the course of the disease, are most likely to exert a favorable effect.
KW - bioenergetics
KW - neurohormonal stimulation
KW - ventricular remodeling
UR - http://www.scopus.com/inward/record.url?scp=0029050113&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029050113&partnerID=8YFLogxK
U2 - 10.1007/BF00877859
DO - 10.1007/BF00877859
M3 - Article
C2 - 8562464
AN - SCOPUS:0029050113
SN - 0920-3206
VL - 9
SP - 489
EP - 492
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 3 Supplement
ER -
